caspofungin acetate
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fungal Infection
Conditions
Fungal Infection
Trial Timeline
May 1, 2004 → Jul 1, 2006
NCT ID
NCT00292071About caspofungin acetate
caspofungin acetate is a phase 2 stage product being developed by Merck for Fungal Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00292071. Target conditions include Fungal Infection.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00635648 | Phase 3 | Completed |
| NCT00330395 | Phase 2 | Completed |
| NCT00250432 | Phase 3 | Completed |
| NCT00379964 | Phase 3 | Completed |
| NCT00292071 | Phase 2 | Completed |
| NCT00082524 | Phase 2 | Completed |
Competing Products
20 competing products in Fungal Infection